HR-8083-119
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Natural Resources, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Ashley Hinson (R-IA)
What it does
This bill would direct the FDA to give priority review to applications from drug manufacturers seeking to sell routine oral contraceptives over the counter (without a prescription) for adults 18 and older, and would waive the associated FDA application fee. Drugs that are emergency contraceptives or approved for induced abortion would be excluded. People under 18 would still require a prescription. The bill would also require the Government Accountability Office (GAO) to study and report to Congress within one year on how much federal money has been spent on contraception reimbursement, inventory, provider training, and patient education over the past 15 years across eight major federal programs.
Who benefits
Adult women (18+) who currently need a prescription to access routine oral contraceptives — particularly those without easy access to a doctor or clinic, those in rural or underserved areas, and those with limited time or transportation. Uninsured or underinsured women who pay out-of-pocket for doctor visits to obtain prescriptions. Pharmacies and retail outlets that could sell contraceptives without prescription requirements. Generic and brand-name oral contraceptive manufacturers who would receive expedited, fee-waived FDA review. Congress and policymakers who would gain a comprehensive data picture of federal contraceptive spending from the GAO study.
Who is hurt
Physicians and OB-GYNs who currently conduct the office visits required to prescribe oral contraceptives may see a reduction in patient volume. Adolescents under 18 would not benefit from the over-the-counter change and would still require a prescription. Women who rely on prescription coverage through insurance to offset contraceptive costs could face higher out-of-pocket expenses if OTC status removes the insurance reimbursement obligation under the ACA's preventive care mandate. Manufacturers of competing non-oral contraceptive methods (IUDs, implants, patches) could face indirect competitive pressure.
Supporters argue
Supporters argue that routine oral contraceptives have a decades-long safety record and are already available without a prescription in over 100 countries, making the U.S. prescription requirement an unnecessary barrier to access. They contend that the FDA's own 2023 approval of Opill (norgestrel) as an OTC contraceptive demonstrated the agency's capacity to make this determination, and that expediting and fee-waiving additional applications would accelerate access for the millions of women who skip or delay contraception due to cost or logistical barriers to obtaining a prescription. The GAO study, they argue, would provide Congress with objective data to guide future contraceptive funding decisions.
Opponents argue
Opponents argue that moving oral contraceptives to OTC status could undermine insurance coverage obligations — because ACA preventive care mandates apply to prescription drugs, OTC reclassification may allow insurers to stop covering these drugs, shifting costs directly to consumers and potentially making contraception more expensive for many women. They also contend that annual prescription visits serve as an important touchpoint for broader women's health screenings, and that removing this requirement could reduce detection of conditions such as hypertension, which is a contraindication for some hormonal contraceptives. Critics further note the bill does not address affordability or insurance coverage gaps that OTC status may create.
Constitutional context
Congress has broad authority to regulate drug approval processes and federal spending programs under the Commerce Clause (Art. I, §8, cl. 3) and the Taxing and Spending Clause (Art. I, §8, cl. 1). The FDA fee waiver provision involves a modest exercise of spending power. Post-Loper Bright (2024), any FDA rulemaking implementing the priority review process would face independent judicial scrutiny rather than automatic deference, though the bill's directive is relatively narrow and specific.
Checks and balances
The executive branch (HHS/FDA) gains a directed mandate to prioritize certain applications and waive fees, but Congress retains oversight through the GAO study requirement; the FDA's substantive safety and efficacy review authority is unchanged.
Historical precedent
The FDA approved Opill (norgestrel) as the first over-the-counter daily oral contraceptive in the U.S. in July 2023, establishing a direct regulatory precedent for the type of application this bill would fast-track.